Nanobiotix (NASDAQ:NBTX) Shares Down 6.6% – What’s Next?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s share price fell 6.6% during trading on Monday . The company traded as low as $31.50 and last traded at $31.5760. 72,017 shares traded hands during trading, an increase of 46% from the average session volume of 49,416 shares. The stock had previously closed at $33.79.

Analyst Ratings Changes

A number of brokerages have recently commented on NBTX. Guggenheim boosted their price objective on Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. TD Cowen reissued a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $25.00.

Nanobiotix Stock Performance

The firm has a 50 day moving average of $30.61 and a two-hundred day moving average of $24.90.

Nanobiotix (NASDAQ:NBTX) last issued its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The business had revenue of $3.42 million during the quarter. As a group, analysts forecast that Nanobiotix S.A. – Sponsored ADR will post 0.53 EPS for the current year.

Institutional Investors Weigh In On Nanobiotix

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Optiver Holding B.V. purchased a new stake in Nanobiotix in the third quarter valued at approximately $101,000. Marshall Wace LLP purchased a new stake in Nanobiotix in the fourth quarter valued at approximately $220,000. Millennium Management LLC purchased a new stake in Nanobiotix in the fourth quarter valued at approximately $390,000. Finally, Royal Bank of Canada lifted its stake in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the last quarter. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.